IP Library Granted Patent US 9,731,036
Granted Patent B2
US 9,731,036 · App. 14/287,901 · Granted Aug 15, 2017

CEACAM1 mediated protective immunity

Inventor: Gal Markel (Haifa, IL)
A61K51/10A61K35/17A61K38/1774A61K49/0004A61K49/0052A61K49/0056A61K49/0058A61K51/04A61K51/088C07K14/70503C07K16/3007C12N5/0635C12N5/0636G01N33/56972G01N33/574G01N33/57492A61K2035/122C07K2317/54C07K2317/732G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,731,036
App. No.
14/287,901
Granted
Aug 15, 2017
Kind
B2
Abstract

The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue.

Claims (1)

1. A method for inducing a protective immunity from the activity of activated Natural Killer cells in a target tissue to be transplanted, wherein said method comprises the induction of CEACAM1 protein production in said target tissue to be transplanted by transforming said target tissue to be transplanted with a nucleic acid encoding CEACAM1 protein by particle mediated transfer of an expression vector containing said nucleic acid, and wherein said Natural Killer cells express CEACAM1.

Continuity (3)
Continuation 11423395 · Jun 9, 2006
Provisional Application 60689316 · Jun 9, 2005
Related Publication 20150150912A1 · Jun 4, 2015